{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T10:43:53Z","timestamp":1789728233195,"version":"4.0.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2009,12,1]],"date-time":"2009-12-01T00:00:00Z","timestamp":1259625600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1186\/1471-2334-9-198","type":"journal-article","created":{"date-parts":[[2009,12,10]],"date-time":"2009-12-10T12:57:50Z","timestamp":1260449870000},"source":"Crossref","is-referenced-by-count":91,"title":["Combination antiretroviral drugs in PLGA nanoparticle for HIV-1"],"prefix":"10.1186","volume":"9","author":[{"given":"Christopher J","family":"Destache","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd","family":"Belgum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemarie","family":"Shibata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akhilesh","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alekha","family":"Dash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,12,9]]},"reference":[{"key":"963_CR1","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1038\/35073639","volume":"410","author":"P Piot","year":"2001","unstructured":"Piot P, Bartos M, Ghys PD, Walker N, Schwartlander B: The global impact of HIV\/AIDS. Nature. 2001, 410: 968-973. 10.1038\/35073639.","journal-title":"Nature"},{"key":"963_CR2","first-page":"900","volume":"18","author":"RY Chen","year":"2002","unstructured":"Chen RY, Westfall AO, Raper JL, Cloud GA, Chatham AK, Acosta EP, et al: Immunologic and virologic consequences of temporary antiretroviral treatment interruption in clinical practice. AIDS Trd Hum Retroviruses. 2002, 18: 900-916.","journal-title":"AIDS Trd Hum Retroviruses"},{"key":"963_CR3","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1080\/13550280590900436","volume":"11","author":"L Chulamokha","year":"2005","unstructured":"Chulamokha L, DeSimone JA, Ponerantz RJ: Antiretroviral therapy in the developing world. J Neurovirol. 2005, 11: 76-80. 10.1080\/13550280590900436.","journal-title":"J Neurovirol"},{"key":"963_CR4","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1016\/S0140-6736(01)06413-3","volume":"358","author":"J Fellay","year":"2001","unstructured":"Fellay J, Boubaker K, Ledergerber B, Bernasconi E, Furrer H, Battegay M, et al: Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study. Lancet. 2001, 358: 1322-1327. 10.1016\/S0140-6736(01)06413-3.","journal-title":"Lancet"},{"key":"963_CR5","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1126\/science.3014648","volume":"233","author":"S Gartner","year":"1986","unstructured":"Gartner S, Markovits P, Markovitz DM, Kaplan MH, Gallo RC, Popovic M: The role of mononuclear phagocytes in HTLV-III\/LAV infection. Science. 1986, 233: 215-219. 10.1126\/science.3014648.","journal-title":"Science"},{"key":"963_CR6","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1073\/pnas.86.7.2383","volume":"86","author":"H Kuhnel","year":"1989","unstructured":"Kuhnel H, von Briesen H, Dietrich U, Meichsner C, Adamski M, Kreutz R, et al: Molecular cloning of two Wet African human immunodeficiency virus type 2 isolates that replicate well in macrophages: a Gambian isolate, from a patient with neurologic acquired immunodeficiency syndrome, and a highly divergent Ghanian isolate. Proc Natl Acad Sci USA. 1989, 86: 2382-2387. 10.1073\/pnas.86.7.2383.","journal-title":"Proc Natl Acad Sci USA"},{"key":"963_CR7","doi-asserted-by":"crossref","first-page":"323","DOI":"10.4049\/jimmunol.137.1.323","volume":"137","author":"JK Nicholson","year":"1986","unstructured":"Nicholson JK, Cross GD, Callaway CS, McDougal JS: In vitro infection of human monocytes with human T lymphotropic virus type III\/lymphadenopathy-associated virus (HTLV-III\/LAV). J Immunol. 1986, 137: 323-329.","journal-title":"J Immunol"},{"key":"963_CR8","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/0923-2516(90)90025-E","volume":"141","author":"J von Briesen","year":"1990","unstructured":"von Briesen J, Andreesen R, Esser R, Brugger W, Meichsner C, Becker K, Rubsamen-Waigmann H: Infection of monocytes\/macrophages by HIV in vitro. Res Virol. 1990, 141: 225-231. 10.1016\/0923-2516(90)90025-E.","journal-title":"Res Virol"},{"key":"963_CR9","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1093\/infdis\/169.4.746","volume":"169","author":"K McGann","year":"1994","unstructured":"McGann K, Collman AR, Kolson DL, Gonzalez-Scarano F, Coukos G, Coutifaris C, et al: Human immunodeficiency virus type 1 causes productive infection of macrophages in primary placental cell cultures. J Infect Dis. 1994, 169: 746-753.","journal-title":"J Infect Dis"},{"key":"963_CR10","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1089\/aid.1994.10.1305","volume":"10","author":"G Milman","year":"1994","unstructured":"Milman G, Sharma O: Mechanisms of HIV\/SIV mucosal transmission. AIDS Res Hum Retroviruses. 1994, 10: 1305-1312. 10.1089\/aid.1994.10.1305.","journal-title":"AIDS Res Hum Retroviruses"},{"key":"963_CR11","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1007\/s11481-006-9032-4","volume":"1","author":"JD Kingsley","year":"2006","unstructured":"Kingsley JD, Dou H, Morehead J, Rabinow B, Gendelman HE, Destache CJ: Nanotechnology: a focus on nanoparticles as a drug delivery system. J Neuroimmun Pharmacol. 2006, 1: 340-350. 10.1007\/s11481-006-9032-4.","journal-title":"J Neuroimmun Pharmacol"},{"key":"963_CR12","first-page":"134","volume":"40","author":"PH Beck","year":"1994","unstructured":"Beck PH, Kreuter J, Muller WEG, Schatton W: Improved peroral delivery of avoral with polybutylcyanoacrylate nanoparticles. Eur J Pharm Biopharm. 1994, 40: 134-137.","journal-title":"Eur J Pharm Biopharm"},{"key":"963_CR13","first-page":"219","volume-title":"Colloidal Drug Delivery Systems","author":"J Kreuter","year":"1994","unstructured":"Kreuter J: Nanoparticles. Colloidal Drug Delivery Systems. Edited by: Kreuter J. 1994, New York: Marcel Dekker, Inc., 219-342."},{"key":"963_CR14","doi-asserted-by":"publisher","first-page":"2827","DOI":"10.1182\/blood-2006-03-012534","volume":"108","author":"H Dou","year":"2006","unstructured":"Dou H, Destache CJ, Morehead JR, Mosley RL, Boska MD, Kingsley J, et al: Development of a macrophage-based nanoparticle platform for anti-retroviral drug delivery. Blood. 2006, 108: 2827-2835. 10.1182\/blood-2006-03-012534.","journal-title":"Blood"},{"key":"963_CR15","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.virol.2006.08.012","volume":"358","author":"H Dou","year":"2007","unstructured":"Dou H, Morehead J, Destache CJ, Kingsley JD, Skyakhtenko L, Zhou U, et al: Laboratory investigations for the morphologic, pharmacokinetic, and anti-retroviral properties of indinavir nanoparticles in human monocytes-derived macrophages. Virology. 2007, 358: 148-158. 10.1016\/j.virol.2006.08.012.","journal-title":"Virology"},{"key":"963_CR16","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1189\/jlb.0206110","volume":"80","author":"S Gorantla","year":"2006","unstructured":"Gorantla S, Dou H, Boska M, Destache CJ, Nelson JA, Poluektova L, et al: Quantitative magnetic resonance and SPECT imaging for macrophage tissue migration and nanoformulated drug delivery. J Leukoc Biol. 2006, 80: 1165-1174. 10.1189\/jlb.0206110.","journal-title":"J Leukoc Biol"},{"key":"963_CR17","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/S0005-2736(01)00432-1","volume":"1558","author":"J-F Gagne","year":"2002","unstructured":"Gagne J-F, Desormeaux A, Perron Tremblay MJ, Bergeron MG: Targeted delivery of indinavir to HIV-1 primary reservoirs with immunoliposomes. Biochem Biophy Acta. 2002, 1558: 198-210. 10.1016\/S0005-2736(01)00432-1.","journal-title":"Biochem Biophy Acta"},{"key":"963_CR18","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1128\/AAC.40.6.1467","volume":"40","author":"AR Bender","year":"1996","unstructured":"Bender AR, von Briesen H, Kreuter J, Duncan IB, Rubsamen-Waigmann H: Efficiency of nanoparticles as a carrier system for antiretroviral agents in human immunodeficiency virus-infected human monocytes\/macrophages in vitro. Antimicrob Agents Chemother. 1996, 40: 1467-1471.","journal-title":"Antimicrob Agents Chemother"},{"key":"963_CR19","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.ijpharm.2004.11.025","volume":"290","author":"Y-C Kuo","year":"2005","unstructured":"Kuo Y-C: Loading efficiency of stavudine on polybutylcyanoacrylate and methmethacrylate-sulfopropylmethacrylate copolymer nanoparticles. Int J Pharmaceut. 2005, 290: 161-172. 10.1016\/j.ijpharm.2004.11.025.","journal-title":"Int J Pharmaceut"},{"key":"963_CR20","doi-asserted-by":"publisher","first-page":"2638","DOI":"10.1007\/s11095-006-9101-7","volume":"23","author":"LK Shah","year":"2006","unstructured":"Shah LK, Amiji MM: Intracellular delivery of saquinavir in biodegradable polymeric nanoparticles for HIV\/AIDS. Pharm Res. 2006, 23: 2638-2645. 10.1007\/s11095-006-9101-7.","journal-title":"Pharm Res"},{"key":"963_CR21","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.jchromb.2006.10.022","volume":"848","author":"DR Weller","year":"2007","unstructured":"Weller DR, Brundage RC, Balfour J, H H, Vezina HE: An isocratic liquid chromatography method for determining HIV non-nucleoside reverse transcriptase inhibitor and protease inhibitor concentrations in human plasma. J Chromatrograph B Analyt Technol Biomed Life Sci. 2007, 848: 369-373. 10.1016\/j.jchromb.2006.10.022.","journal-title":"J Chromatrograph B Analyt Technol Biomed Life Sci"},{"key":"963_CR22","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1084\/jem.167.4.1428","volume":"167","author":"HE Gendelman","year":"1988","unstructured":"Gendelman HE, Orenstein JM, Martin MA, Ferrua C, Mitra R, Phipps T, et al: Efficient isolation and propagation of human immunodeficiency virus on recombinant colony-stimulating factor-1-treated monocytes. J Exp Med. 1988, 167: 1428-1441. 10.1084\/jem.167.4.1428.","journal-title":"J Exp Med"},{"key":"963_CR23","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/0022-1759(86)90368-6","volume":"89","author":"F Denizot","year":"1986","unstructured":"Denizot F, Lang R: Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J Immunol Methods. 1986, 89: 271-277. 10.1016\/0022-1759(86)90368-6.","journal-title":"J Immunol Methods"},{"key":"963_CR24","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/0022-1759(89)90397-9","volume":"119","author":"MN Hansen","year":"1989","unstructured":"Hansen MN, Nielsen SE, Berg K: Re-examination and further development of a precise and rapid dye method for measuring cell growth\/cell kill. J Immunol Methods. 1989, 119: 203-210. 10.1016\/0022-1759(89)90397-9.","journal-title":"J Immunol Methods"},{"key":"963_CR25","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1002\/jps.2600710717","volume":"71","author":"P Couvreur","year":"1982","unstructured":"Couvreur P, Kante B, Crislain L, Roland M, Speiser P: Toxicity of polyalkylcyanoacrylate nanoparticles II: doxorubicin-loaded nanoparticles. J Pharm Sci. 1982, 71: 790-792. 10.1002\/jps.2600710717.","journal-title":"J Pharm Sci"},{"key":"963_CR26","doi-asserted-by":"publisher","first-page":"101","DOI":"10.3109\/02652049309015316","volume":"10","author":"P Beck","year":"1993","unstructured":"Beck P, Kreuter J, Reszka R, Fichtner I: Influence of polybutylcyanoacrylate nanoparticles and liposomes on the efficacy and toxicity of anticancer drug mitoxantrone in murine tumour models. J Microencapsul. 1993, 10: 101-114. 10.3109\/02652049309015316.","journal-title":"J Microencapsul"},{"key":"963_CR27","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1016\/S0264-410X(00)00433-3","volume":"19","author":"MA Conway","year":"2001","unstructured":"Conway MA, Madrigal-Estebas L, McClean S, Brayden DJ, Mills KH: Protection against Bordetella pertussis infection following parenteral or oral immunization with antigens entrapped in biodegradable particles: effect of formulation and route of immunization on induction of Th1 and Th2 cells. Vaccine. 2001, 19: 1940-1950. 10.1016\/S0264-410X(00)00433-3.","journal-title":"Vaccine"},{"key":"963_CR28","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1007\/s11095-005-8343-0","volume":"22","author":"D Shenoy","year":"2005","unstructured":"Shenoy D, Little S, Langer R, Amiji M: Poly(ethylene oxide)-modified poly(\u03b2-amino ester) nanoparticles as a pH-sensitive system for tumor-targeted delivery of hydrophobic drugs: Part 2. In vivo distribution and tumor localization studies. Pharm Res. 2005, 22: 2107-2114. 10.1007\/s11095-005-8343-0.","journal-title":"Pharm Res"},{"key":"963_CR29","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/nature03794","volume":"436","author":"S Sengupta","year":"2005","unstructured":"Sengupta S, Eavarone D, Capila I, Zhao G, Kiziltepe T, Sasisekharan R: Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system. Nature. 2005, 436: 568-572. 10.1038\/nature03794.","journal-title":"Nature"},{"key":"963_CR30","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1016\/j.addr.2004.02.014","volume":"56","author":"L Brannon-Pepas","year":"2004","unstructured":"Brannon-Pepas L, Blanchette JO: Nanoparticle and targeted systems for cancer therapy. Adv Drug Del Rev. 2004, 56: 1649-1659. 10.1016\/j.addr.2004.02.014.","journal-title":"Adv Drug Del Rev"},{"key":"963_CR31","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1038\/44755","volume":"401","author":"TW Chun","year":"1999","unstructured":"Chun TW, Davey RT, Engel D, Lane HC, Fauci AS: Re-emergence of HIV after stopping therapy. Nature. 1999, 401: 874-875. 10.1038\/44755.","journal-title":"Nature"},{"key":"963_CR32","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1056\/NEJM199905273402101","volume":"340","author":"L Zhang","year":"1999","unstructured":"Zhang L, Ramratnam B, Tenner-Racz K, He Y, Vesanen M, Lewin S, et al: Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N Engl J Med. 1999, 340: 1605-1613. 10.1056\/NEJM199905273402101.","journal-title":"N Engl J Med"},{"key":"963_CR33","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/S0140-6736(05)76156-0","volume":"353","author":"V Natarajan","year":"1999","unstructured":"Natarajan V, Bosche M, Metcalf JA, WArd DJ, Lane HC, Kovacs JA: HIV-1 replication in patients with undetectable plasma virus receiving HAART. Lancet. 1999, 353: 119-120. 10.1016\/S0140-6736(05)76156-0.","journal-title":"Lancet"},{"key":"963_CR34","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1097\/00126334-200401010-00004","volume":"35","author":"B Ramratnam","year":"2004","unstructured":"Ramratnam B, Ribeiro R, He T, Chung C, Simon B, Vanderhoeven J, et al: Intensification of antiretroviral therapy accelerates the decay of the HIV-1 latent reservoir and decreases, but does not eliminate, ongoing virus replication. J Acquire Immune Defic Syndr. 2004, 35: 33-37. 10.1097\/00126334-200401010-00004.","journal-title":"J Acquire Immune Defic Syndr"},{"key":"963_CR35","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1086\/527324","volume":"197","author":"T-W Chun","year":"2008","unstructured":"Chun T-W, Nickle DC, Justement JS, Meyers JH, Roby G, Hallahan CW, et al: Persistence of HIV in gut-associated lymphoid tissue despite long-term antiretroviral therapy. J Infect Dis. 2008, 197: 714-720. 10.1086\/527324.","journal-title":"J Infect Dis"},{"key":"963_CR36","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.drugalcdep.2006.02.003","volume":"84","author":"A Palepu","year":"2006","unstructured":"Palepu A, Tyndall MW, Joy R, Kerr T, Wood E, Press N, et al: Antiretroviral adherence and HIV treatment outcomes among HIV\/HCV co-infected injection drug users: the role of methadone maintenance therapy. Drug Alcohol Depend. 2006, 84: 188-194. 10.1016\/j.drugalcdep.2006.02.003.","journal-title":"Drug Alcohol Depend"},{"key":"963_CR37","first-page":"1145","volume":"79","author":"P Farmer","year":"2001","unstructured":"Farmer P, Leandre F, Mukherjee J, Gupta R, Tarter L, Kim JY: Community-based treatment of advanced HIV disease: introducing DOT-HAART (directly observed therapy with highly active antiretroviral therapy). Bulletin World Health Org. 2001, 79: 1145-1151.","journal-title":"Bulletin World Health Org"},{"key":"963_CR38","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1089\/aid.2006.0231","volume":"2","author":"J Rockstron","year":"2008","unstructured":"Rockstron J, Dejesus E, Donatacci L, Wat C, Bertasso A, Labriola-Tompkins E, et al: Adherence to Enfuvirtide and its impact on treatment efficacy. AIDS Res Hum Retroviruses. 2008, 2: 141-148. 10.1089\/aid.2006.0231.","journal-title":"AIDS Res Hum Retroviruses"},{"key":"963_CR39","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.ejpb.2009.03.006","volume":"72","author":"L Baert","year":"2009","unstructured":"Baert L, van't Klooster G, Dries W, Francois M, Wouters A, Basstanie E, et al: Development of a long-acting injectable formulation with nanoparticles of rilpivirine (TMC278) for HIV treatment. Eur J Pharm Biopharm. 2009, 72: 502-508. 10.1016\/j.ejpb.2009.03.006. Epub 2009 Mar 2027.","journal-title":"Eur J Pharm Biopharm"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2334-9-198\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2334-9-198.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2334-9-198","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2334-9-198.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,27]],"date-time":"2023-05-27T21:16:48Z","timestamp":1685222208000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/1471-2334-9-198"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["963"],"URL":"https:\/\/doi.org\/10.1186\/1471-2334-9-198","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,12]]},"article-number":"198"}}